CHMP recommends GSK’s Nucala (mepolizumab) for three eosinophil-driven diseases


GlaxoSmithKline (GSK) has announced that the Committee for Medicinal Products for Human Use (CHMP) has issued positive feedback on the use of Nucala (mepolizumab) in providing the first targeted treatment for three eosinophil-driven diseases. These consist of eosinophilic granulomatosis with polyangiitis (EGPA) , hypereosinophilic syndrome (HES), and chronic rhinosinusitis with nasal polyps (CRSwNP).

Eosinophil-driven diseases are inflammatory conditions associated with elevated levels of eosinophils, a type of white blood cell.

read more